ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00155714
Recruitment Status : Withdrawn (We can't obtained the test drug (Vadenafil) from Bayer. They decided not to carry out this trail in Taiwan. Therefore this trail has never been started.)
First Posted : September 12, 2005
Last Update Posted : March 16, 2010
Sponsor:
Information provided by:
National Taiwan University Hospital

Brief Summary:
The aim of this trial is to evaluate the efficacy of type-5 phosphodiesterase inhibitors (sildenafil) in primary and secondary pulmonary hypertension

Condition or disease Intervention/treatment Phase
Primary and Secondary Pulmonary Hypertension Drug: type-5 phosphodiesterase Inhibitor (Sildenafil) Not Applicable

Detailed Description:
Patients with primary and secondary pulmonary hypertension will be recruited and admitted to the ICUs of the National Taiwan University Hospital. Each patient will undergo Swan-Ganz catheterization and hemodynamic monitoring during administration of sildenafil. Efficacy of inhaled NO and Iloprost will also be compared.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Efficacy of Type-5 Phosphodiesterase Inhibitors (Sildenafil and Vadenafil) in Primary and Secondary Pulmonary Hypertension
Study Start Date : November 2002
Estimated Study Completion Date : May 2005





Primary Outcome Measures :
  1. mean pulmonary artery pressure
  2. 6 min walking distance
  3. WHO functional status
  4. PaO2

Secondary Outcome Measures :
  1. cardiac output
  2. VO2max


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:Patients with primary and secondary pulmonary arterial hypertension

Exclusion Criteria:Unstable patients or patients with allergy to sildenafil


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00155714


Locations
Taiwan
Ping-Hung Kuo
Taipei, Taiwan, 100
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Ping-Hung Kuo, MD National Taiwan University Hospital

ClinicalTrials.gov Identifier: NCT00155714     History of Changes
Other Study ID Numbers: 9100017321
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: March 16, 2010
Last Verified: January 2010

Keywords provided by National Taiwan University Hospital:
pulmonary arterial hypertension
type-5 phosphodiesterase Inhibitors
Sildenafil

Additional relevant MeSH terms:
Hypertension
Neoplasm Metastasis
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Neoplastic Processes
Neoplasms
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Sildenafil Citrate
Phosphodiesterase Inhibitors
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents